

Drug and Therapeutics Committee – Minutes – Confirmed

Date / Time	Thursday 14 th November 2019 8:15am – 9:30am
Venue	Pathology Meeting Room, Pathology Dept, HRI
Chair	Prof M Lind, Vice Chair, Professor of Oncology
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician
Quorate: Yes / No	Yes
Attendance	Ms J Morgan, Professional Secretary, Senior Principal Pharmacist - Formulary Dr O Ogunbambi, Consultant Rheumatologist Dr A Samson, Infectious Diseases Consultant Mr P O'Brien, Deputy Chief Pharmacist Dr S Raise, GP ER CCG (via phone link) Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Ms E Opere-Sakyi, Medicines Optimisation Pharmacist, NECS Dr B Ali, GP Hull CCG (via phone link)
Guests	Pre Registration Pharmacists: Katie Clark, Hadassah Ezekiel, Nirvana Islam, Emma Knowles, Mared McNeil, Artiben Patel, Khatija Rafiq, Walleed Shahzad, Rasha Shawki
Apologies	Mr R Kapur, Vascular Surgeon Prof A Morice, Chair, Professor of Respiratory Medicine Mr K McCorry, Medicines Optimisation Pharmacist, NECS Dr F Umerah, Consultant Anaesthetist Dr H Klonin, Consultant Paediatrician Mr S P Gaines, Deputy Chief Pharmacist, Lead Pharmacist Medicine Safety

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2019.11.01	Apologies	As above					11/19
2019.11.02	Declarations of Interest	None					11/19
2019.11.03	Minutes of the previous meeting	Accepted as a true record					11/19
2019.11.04	Action Tracker	<p>Tracker WH has added unlicensed medicines to agenda</p> <p>NICE Guidance TA592 WH has circulated Cemiplimab ARIA form with papers</p> <p>Review of Use of Aprotonin POB emailed Dr Hibbert. There are currently 4 patients on the registry and 1 more who requires adding. This was discussed at cardiothoracics governance where it was agreed that the bookelet and register must be filled in when patient received aprotonin.</p> <p>New Product Requests AM has written to applicants and WH has updated formulary</p> <p>New Product Requests JM has emailed orthopaedics regarding if they wish to use Dibotermin and is awaiting a reply.</p> <p>NICE Guidance AM has written to Prof Bhandari regarding NICE TA 599 Sodiiium Zirconium. Renal pharmacist is working alongside the renal team to update guidelines.</p> <p>NICE Guidance JM confirmed that NG138/NG130/NG141 were discussed by</p>	<p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>	<p>WH</p> <p>WH</p> <p>POB</p> <p>AM</p> <p>JM</p> <p>AM</p> <p>JM</p>	<p>11/19</p> <p>11/19</p> <p>11/19</p> <p>11/19</p> <p>11/19</p> <p>11/19</p>		

		ACAT AOB WH has added Cidofovir to the formulary	Action complete		WH		11/19
2019.11.05	New Product Requests	LAT Gel –Topical Local Anaesthetic-Dr Herrievn Requested to use in place of sedating paediatric patients. The committee felt that the evidence was of poor quality but recognised there may be a need for this treatment within ED. Benralizumab – Add on Therapy for severe Eosinophilic Asthma – Dr S Faruqi Requested after submitting 3 chairs approvals and the publication of TA565 Emicizumab – Severe Haemophilia – Dr D Allsup NHSE have published a strict clinical commissioning policy, HUTH is a centre for the treatment of haemophilia	Invite EH to D&T to provide further information in support of application Approved for use in line with NICE Approved in line with NHSE commissioning policy	ML to write to EH ML to write to applicants/WH to update formulary ML to write to applicants/WH to update formulary	ML ML/WH ML/WH	12/19 12/19 12/19	
2019.11.06	NICE Guidance – October 19	TA604 Idelalisib for treating refractory follicular lymphoma (Not Recommended) TA605 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea TA606 Lanadelumab for preventing recurrent attacks of hereditary angioedema JM has emailed Dr P Gordins highlighting this TA and asking if he would like to submit an application TA607 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease TA608 Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal) TA609 Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) NG19 Diabetic foot problems: prevention and management NG1 Gastro-oesophageal reflux disease in children and young people: diagnosis and management – updated to include information on PPI/H2blockers	Noted PAS in place. JM to ask Dr Salawu to submit form Noted Noted Noted Noted Noted		JM	12/19 12/19 12/19 12/19 12/19 12/19	11/19 11/19 11/19 11/19 11/19 11/19

		<p>CG137 Epilepsies: diagnosis and management Updated to change CD status of pregabalin/gabapentin</p> <p>CG71 Familial hypercholesterolaemia: identification and management</p> <p>NG142 End of life care for adults: service delivery</p> <p>CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management Updated to include quinolone restrictions and precautions</p> <p>NG144 Cannabis-based medicinal products Document includes the approval of Sativex for MS spasticity to be funded by the CCG. HUTH currently has 1 patient receiving treatment with Epidiolex and has another potential 4 patients who may benefit from its use.</p>	<p>Noted</p> <p>Noted</p> <p>Noted</p> <p>Noted</p> <p>JM to ask Dr Harley to submit application</p>				<p>11/19</p> <p>11/19</p> <p>11/19</p> <p>11/19</p> <p>12/19</p>
2019.11.07	MHRA Drug Safety Update	<p>Ingenol Mebutate Gel – Increased incidence of skin tumours. JM will liaise with dermatology lead pharmacist.</p> <p>Nivolumab – Reports of CMV gastrointestinal infection or reactivation. ML informed the committee that the immunotherapies working party were putting together a protocol</p> <p>Prescribing Medicines in Renal Impairment Using the Appropriate Estimate of Renal Function to Avoid the Risk of Adverse Drug Reactions JM stated that all current trust guidelines used creatinine clearance as a measure of renal function. Lorenzo blood results however still came through with eGfr result.</p> <p>Adrenaline Autoinjectors – recent actions taken to support safety HUTH currently has 3 different devices on formulary due to supply issues</p>	<p>JM to request dermatology informed</p> <p>Noted</p> <p>JM to speak to discuss with pathology</p> <p>Noted</p>		JM	12/19	<p>11/19</p> <p>12/19</p> <p>11/19</p>
2019.11.08	SDA Ranitidine	<p>Ranitidine has been the subject of several drug recalls this month. Patients admitted are either using their own supply or being switched to a PPI where appropriate. The trust intends to add Famotidine and Nizatidine to formulary however neither of these two products are licensed in children. Esomeprazole granules are an option as is cimetidine liquid but concerns were raised regarding interactions with other medicines.</p>	<p>POB to send SR details of the information provided to Womens & Childrens regarding the switch to PPI</p>		POB	12/19	
	Minutes from	None this month					11/19

2019.11.09	SMPC							11/19
2019.11.10	Minutes from HERPC	None this month						
2019.11.11	Notes from Formulary Review Meeting	A review of chapters 11-15 had taken place and some older items had been removed from formulary. JM and WH still need to review vaccine section	Vaccine chapter to be reviewed			JM/WH	01/20	
2019.11.12	Unlicensed Medicines	JM had written a paper regarding appropriate use of unlicensed medicines and informed the committee that a resource pack was also being put together.	Noted					11/19
2019.11.13	Regional Medicines Optimisation Committees	Medicines Optimisation Reviews To reduce Inappropriate Polypharmacy & Promote Safe DePrescribing Sodium Oxybate in Adult Patients – HUTH current have 1 patient receiving treatment via IFR	Noted					11/19
2019.11.14	Correspondence received	CRFR Modulator Therapy Dr Shiferaw Orkambi Letter Access Agreement for CFTR Although the products Kalydeco, Orkambi and Symkevi have all been previously viewed positively by NICE until now there has been no financial agreement in place. The NHSE has now come to an agreement with the manufacturer and HUTH anticipate they will be treating approximately 30 patients via homecare shortly.	Approved ML to write to Dr Shiferaw to confirm D&T approval.					11/19
2019.11.15	Chairs approvals	None this month						11/19
2019.11.16	Issues to escalate to OQC	No issues to escalate but CF drug funding and NG144 to be highlighted						11/19
2019.11.17	Any Other Business	POB informed the committee that a HUTH patient had recently received glucarpidase to treat increased levels of methotrexate. The treatment was successful but the patient is still being treated by HRI Interventional neuroradiology had used Eptifibatide in aneurysm coiling JM has requested interventional neuroradiology to submit some evidence for this indication, but none received.	Noted ML to write to interventional neuroradiology requesting evidence			ML	12/19	11/19

		Eluxadoline no longer available remove from formulary	WH to remove from formulary		WH	12/19	
	Date and Time of Next Meeting	Date: Thursday 12 th December 2019 Time: 8.15-9.30am Venue: Pathology Meeting Room. Pathology Building, HRI					